MECHANISMS OF RECEPTOR-DEPENDENT REGULATION OF BILE ACID AND XENOBIOTIC METABOLISM. THE ROLE OF CYP3A4 EXPRESSION IN THE SAFETY AND EFFECTIVENESS OF PHARMACOTHERAPY
DOI:
https://doi.org/10.56782/pps.118Keywords:
CYP3A4, expression, regulation, nuclear receptors, PXR, FXR, xenobiotic biotransformation, drug metabolism, bile acids, pharmacotherapyAbstract
The isoenzyme CYP3A4 is an important monooxygenase responsible for the metabolism of a large variety of endogenous and exogenous compounds (xenobiotics), including more than 50% of known drugs. The highest activity of CYP3A4 in human was found in hepatocytes and enterocytes. CYP3A4 gene expression is regulated by diverse exogenous and endogenous factors, including bile acids and several drugs, acting via nuclear receptors, such as, for example, PXR or FXR. Understanding the mechanisms of CYP3A4 gene expression is essential for ensuring the safety and effectiveness of pharmacotherapy.
KEYWORDS: CYP3A4, expression, regulation, nuclear receptors, PXR, FXR, xenobiotic biotransformation, drug metabolism, bile acids, pharmacotherapy
Downloads
References
Długosz A. Stokłosa A. Kłodnicka A. Ginekol. Pol. 2007, 78, 632-636.
Parkinson P. Ogilvie BW. Buckley DB. Kazmi F. Czerwiński M., Parkinson O. w Klaassen C. [Edit.]. Casarett & Doull’s Toxicology, The Basic Science of Poisons, McGraw-Hill Education, London 2013.
Anzenbacher P. Eva Anzenbacherová E. w: Anzenbacher P. Tanger UM. [Edit.]: Metabolism of drugs and other xenobiotics. Wiley-VCH Verlag GmbH & Co. KGaA, Dresden 2012. DOI: https://doi.org/10.1002/9783527630905
Maruyama M. Matsunaga T. Harada E. Ohmori S. Biol. Pharm. Bull. 2007, 30(11), 2091-207. DOI: https://doi.org/10.1248/bpb.30.2091
Lu C. Miwa GT. Prakash S.R. Gani L-S. Balani SK. Drug. Metab. Dispos. 2007, 35(1), 79-85. DOI: https://doi.org/10.1124/dmd.106.011346
Michalets EL. Pharmacotherapy 1998, 18, 84-112. DOI: https://doi.org/10.1002/j.1875-9114.1998.tb03830.x
Skagen KJ. Interindividual Variability in the Cytochrome P450 3A4 drug metabolizing enzyme: effect of the CYP3A4*1G genetic variant. University of Montana Missoula 2014, http://scholarworks.umt.edu.
Lewis DF. Pharmacogenomic 2004, 5(3), 305-318. DOI: https://doi.org/10.1517/phgs.5.3.305.29827
McKinnon RA. Sorich MJ., Ward MB. J Pharm. Pract. Res. 2008, 38(1), 55-57. DOI: https://doi.org/10.1002/j.2055-2335.2008.tb00798.x
Meunier B. de Visser SP. Sason Shaik S. Chem. Rev. 2004, 104, 3947-3980. DOI: https://doi.org/10.1021/cr020443g
Tompkins LM., Wallace AD. J. Biochem. Mol. Toxicol. 2007, 21(4), 176-81. DOI: https://doi.org/10.1002/jbt.20180
Zanger UM. Schwab M. Pharmacol. Ther. 2013, 138, 103-141. DOI: https://doi.org/10.1016/j.pharmthera.2012.12.007
Thummel KE.J. Clin. Invest. 2007, 117(11), 3173-3176. DOI: https://doi.org/10.1172/JCI34007
Ohtsuki S. Schaefe, O. Kawakami H. Inoue T. Liehner S. Saito A. Ishiguro N. Kishimoto W. Ludwig-Schwellinger E. Ebner T. Terasaki T. Drug Metab. Dispos. 2012, 40, 83-92. DOI: https://doi.org/10.1124/dmd.111.042259
Kliewer SA. Goodwin B. Willson TM. Endocrine Rev. 2002, 23, 687-702. DOI: https://doi.org/10.1210/er.2001-0038
GenAtlas human gene database, http://genatlas.medecine.univ-paris5.fr/.
William JA. Ring BJ. Cantrell VE. Jones DR. Eckstein J. Ruterbories K. Drug Metab. Dispos. 2002, 30, 883-891. DOI: https://doi.org/10.1124/dmd.30.8.883
Daly AK. Clin. Pharmacokinet. 2006, 45, 13-31. DOI: https://doi.org/10.2165/00003088-200645010-00002
Medsafe. Drug Metabolism - The Importance of Cytochrome P450 3A4. Prescriber Update 35(1), 4-6.
Soldin OP. Chung SH. Mattison DR. J. Biomed. Biotech. 2011, 2011, 1-14. DOI: https://doi.org/10.1155/2011/187103
Johnson EF. Biochem. Biophys. Res. Commun. 2005, 338, 331-336. DOI: https://doi.org/10.1016/j.bbrc.2005.08.190
Guengerich FP. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 1-17. DOI: https://doi.org/10.1146/annurev.pharmtox.39.1.1
Orans J. Teotico DG. Redinbo MR. Mol. Endocrinol. 2005, 19, 2891-2900. DOI: https://doi.org/10.1210/me.2005-0156
Sinz M.W. Drug Metabol. Rev. 2013, 45(1), 3-14. DOI: https://doi.org/10.3109/03602532.2012.743560
Kobayashi T. Kodani Y. Nozawa A. Endo Y. Sawasaki T. FEBS Lett. 2008, 582(18), 2737-2744. DOI: https://doi.org/10.1016/j.febslet.2008.07.003
Luo G. Cunningham M. Kim S. Burn T. Lin J. Sinz M. Hamilton G. Rizzo Ch. Jolley S. Gilbert D. Downey A. Mudra D. Graham R. Karoll K. Xie J. Madan A. Parkinson A. Christ D. Selling B. Lecluyse E. Gan L-S. Drug. Metabol. Dis. 2002, 30(7), 795-804. DOI: https://doi.org/10.1124/dmd.30.7.795
Hasegawa M. Kapelyukh Y. Tahara H. Seibler J. Rode A. Krueger S. Mol. Pharmacol. 2011, 80, 518-528. DOI: https://doi.org/10.1124/mol.111.071845
Kliewer SA. J. Nutr. 2003, 133, 2444S-2447S. DOI: https://doi.org/10.1093/jn/133.7.2444S
Matic M. Mahns A. Tsoli M. Corradin A. Polly P. Rpbertson GR. Int. J. Biochem. Cell Biol. 2007, 39, 478-483. DOI: https://doi.org/10.1016/j.biocel.2006.08.017
Martinez-Jimenez CP. Jover R. Donato MT. Castell JV. Gomez-Lechon MJ. Curr. Drug Metab. 2007, 8, 185-194. DOI: https://doi.org/10.2174/138920007779815986
Haddad A. Davis M. Langman R. Support Care Cancer 2007, 15, 251-257. DOI: https://doi.org/10.1007/s00520-006-0127-5
LeCluyse E.L. Chem. Biol. Interact. 2001, 134, 283-28. DOI: https://doi.org/10.1016/S0009-2797(01)00163-6
Kliewer S.A. Willson T.M. J. Lipid Res. 2002, 43, 359-364. DOI: https://doi.org/10.1016/S0022-2275(20)30141-3
Handshin C. Meyer UA. Arch. Biochem. Biophys. 2005, 433, 387-396. DOI: https://doi.org/10.1016/j.abb.2004.08.030
Zhang S. Pan X. Jeong H. Drug Metab. Dispos. 2015, 43, 743-748. DOI: https://doi.org/10.1124/dmd.114.062836
Hariparsad N. Chu X. Yabut J. Labhart P. Hartley D.P. Dai X. Evers R. Nucleic Acids Res. 2009, 37, 1160-1173. DOI: https://doi.org/10.1093/nar/gkn1047
Soisson SM. Parthasarathy G. Adams AD. Sahoo S. Sitlani A. Sparrow C. Jisong Cui J. Becker JW. PNAS 2008, 105(14), 5337-5342. DOI: https://doi.org/10.1073/pnas.0710981105
Wang YD. Chen WD. Moore DD. Huang W. Cell Res. 2008, 18(11), 1087-1095. DOI: https://doi.org/10.1038/cr.2008.289
Chen J. Zhao K-N. Chen Ch. Ann. Transl. Med. 2014, 2(1), 7-15.
Zhang J. Tian Q. Yung Chan S. Drug Metab. Rev. 2005, 37, 611-703. DOI: https://doi.org/10.1080/03602530500364023
Fukumori S. Murata T. Taguchi M. Hashimoto Y. Drug Metab. Pharmacokinet. 2007, 22, 377-381. DOI: https://doi.org/10.2133/dmpk.22.377
Thummel K.E. Brimer C. Yasuda K. Thottassery J. Senn T. Lin Y. Mol. Pharmacol. 2001, 60, 1399-1406. DOI: https://doi.org/10.1124/mol.60.6.1399
Makishima M. Lu TT. Xie W. Whitfield GK. Domoto H. Evans RM. Science 2002, 296, 1313-1316. DOI: https://doi.org/10.1126/science.1070477
Kobayashi K. Sueyoshi T. Inoue K. Moore R. Negishi M. Mol. Pharmacol. 2003, 64, 1069-1075. DOI: https://doi.org/10.1124/mol.64.5.1069
Moore LB. Parks DJ. Jones SA. Bledsoe RK. Consler TG. Stimmel JB. Goodwin B. Liddle C. Blanchard SG. Wilson TM., Collins JL. Kliewer SA. J. Biol. Chem. 2000a, 275, 15122-15227. DOI: https://doi.org/10.1074/jbc.M001215200
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
